Healthcare Startups funded by Y Combinator (YC) in the San Francisco Bay Area 2024

Notable Labs is building a personalized drug discovery platform to identify treatment options for relapsed and refractory cancer patients — starting with blood cancer — to address the long tail of cancer treatment. We look at a person’s actual cancer cells, test combinations of FDA approved drugs, and see which combinations kill the cancer cells and leave the healthy cells alive. We focus on combinations because cancer is often difficult to target with just one drug and starting with a single drug can lead to resistant clones or relapse. We're building a highly automated lab in Foster City running on our custom software and are currently testing relapsed/refractory cancer patients as well as samples from a variety of pharma/biotech partnerships. https://www.notablelabs.com/careers

Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health. We produce inexpensive, disposable health diagnostic hardware that transforms any smartphone into a portable, real-time health-monitoring device for rapid, accessible, multiplexed analysis of bodily fluids anywhere in the world.

We make oral drugs to treat and prevent viral infections - like COVID-19.

Founded in 2012, Transcriptic has developed the first robotic cloud lab platform for on-demand life science research. It’s powered by the Transcriptic Common Lab Environment (TCLE) a scalable, digital infrastructure that integrates laboratory processes, instruments and IoT technologies into a single user interface. Researchers can carry out scalable, reproducible and rapid experimentation from anywhere in the world. Top ten pharmaceutical companies, as well as emerging biotech companies, are using the platform to gain more reproducibility and flexibility in the design and control of their experiments. By leveraging cloud-based technologies, users can access the power of a fully automated laboratory – whether in their own labs through an on-premise deployment of TCLE or through Transcriptic’s Bioassays services – all through a simple web-based interface. Transcriptic is transforming drug discovery and synthetic biology research by helping scientists focus on accelerating discoveries instead of labor-intensive bench work.

Rev Genomics is a plant biotechnology company that provides breeders, growers, and retailers with novel cultivars to differentiate themselves in high value markets.

Current Description: RTHM provides virtual-first care for complex illness including Long COVID, ME/CFS, POTS, and mast cell activation. Many clinics focus on teaching patients how to better cope with symptoms, which is helpful, but we don’t stop there. We develop collaborations & partnerships so our patients access to the most promising testing and root-cause directed early therapies for their illness(es) with the goal of simplifying and streamlining the most efficient and effective clinical pathways so they can be scaled in the form of low cost online modules overseen remotely by clinicians. In conjunction with clinical care, RTHM operates a clinical lab and collects deep molecular data with robust clinical context to develop AI-powered diagnostics and better ways of predicting which treatments may work best for whom.

GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. The team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.

Auricle is a medical device company building a breakthrough neurostimulation implant to restore hearing in millions of patients who no longer benefit from hearing aids, get less than 60% on a word recognition test, but aren't prepared to make the jump to a cochlear implant. Our approach preserves remaining natural hearing through a reversible and less invasive surgery, addressing the key concerns that hold most patients back from getting a cochlear implant (currently the only treatment option for these patients). The company spun out of Stanford Biodesign having completed two acute human clinical studies demonstrating the approach will work. The team is now focused on developing their full implant system for their first clinical trial. Auricle addresses a currently unserved profile of hearing loss that affects a growing population of 3.5 million patients in the US and represents an immediately accessible $1.2B market opportunity with existing reimbursement.

Quadrant Eye is on a mission to improve eyecare access and fight preventable blindness. We're building the next generation eye exam... inside the average American home. Our team wants to enable patients' best and most visually rich lives. To this end, we're looking for curious and nimble minds to help us develop the world's first fully online eye exam and ultimately deliver high-quality eyecare at scale. Some QE highlights: 🐝 We're a team of surgeons, scientists, venture partners, and hackers who mean business. 💸 Our backers include Y Combinator, Khosla Ventures, and the creator of Google Image Search. 🍥 We're a mission-driven company tackling an eye health market worth $USD137B. 🌟 Our core focus is currently the development of patentable deep tech, and our overall vision is to change eyecare for good.

The iSono Health platform combines automated 3D ultrasound technology with cloud computation and artificial intelligence to empower women and their physicians with early detection and monitoring of breast cancer. Our patented compact ultrasound scanner captures 3D images through automatic scanning of whole breast volume in 1 min. The device connects to a smartphone/tablet/laptop and is controlled by our mobile app. The data is transferred to a secure cloud for image processing and storage. Our machine learning algorithm uses acoustic biomarkers to identify abnormal masses. Our platform’s automated operation and software expands ultrasound use in point-of-care diagnostics as well as monitoring of breast health at home, walk-in and mobile clinics. iSono Health offers women and healthcare providers : Safety: No Radiation Actionable Feedback with AI Fast: 2min Scan Easy to Use

Adni gives healthcare employers a white-labeled employee app – with timesheets, job openings, benefits, resources, and incentives to optimize staffing. Adni predicts clinician churn and automates recognition, improving clinician satisfaction by 45% and reducing turnover by 26%.

Matrubials is an anti-infectives company, focused on human milk peptides as therapeutics to address antimicrobial resistance and modern diseases. Currently the global rise in severe bacterial infections and the drying pipeline of effective treatments are burdensome for healthcare and economics. Sculpted by evolution, milk, first food for the newborn, provides an exemplary solution to address the nutritive and protective challenges an infant is faced with. The anti-pathogenic molecules from milk can be developed into therapeutics geared towards all-age diseases. Our first indication is bacterial vaginosis, a bacterial dysbiosis related inflammation that results in recurrent infections, disruption of homeostasis and long-term clinical complications in women of reproductive age, including but not limited to preterm births, fertility issues and increased rates of STDs. Our next inflection point is the evaluation of rapidly acting and selective candidate peptides in pre-clinical host impact and early safety studies, which can aid clinical and portfolio development towards topical applications.

We are a B2B medical device and data company passionate about providing remote monitoring solutions for the proactive care of chronic disease patients. Our core expertise and IP is in continuous respiratory sensing. Spire Remote Patient Monitoring is used by pulmonologists and patients throughout the United States. To date our sensors have been worn by more than 150,000 people.

Our vision is to provide regenerative medicine treatments that free patients from chronic liver disease and help usher in an era where diseased and damaged tissues can be repaired.

Formerly known as Patchd Medical Wearable technology and AI to predict and prevent sepsis outside of hospital.

Intatct is developing an advanced materials platform to improve the way drugs are delivered and absorbed in the digestive tract. Our vision is to improve the treatment of a wide range of gastrointestinal disorders that are currently underserved.

Nectome is a neuroscience startup that aims to preserve the brain and keep all its memories intact. The company is building the next generation of tools to preserve the connectome. The connectome is all the connections called synapses between neurons in the brain. Researchers from the company is now learning to manipulate individual memories, building advanced brain prosthetics, and reverse-engineering the brain.

If we've learned anything in the last few years it's that spending time with our friends and family is essential to our well-being and happiness. Unfortunately, loud and noisy places like weddings and family gatherings hinder human connection, especially for the hearing impaired. In fact, the biggest unmet need in the entire hearing healthcare industry is hearing in noisy places. AudioFocus helps patients hear in these environments by only enhancing voices nearby the patients and ignoring ones farther away. We do this using acoustics informed machine learning and custom microphone array design. Our goal is to increase the adoption rate of 37M US adults with hearing loss, only 8M use hearing aids today. Founded by Auditory Neuroscientist & AI expert and a Hearing Aid hardware design expert.

Leveraging AI to provide veterinarians with more accurate and affordable diagnostics.

Fella Health is the telehealth clinic for men with obesity. With Fella, patients meet a board-certified obesity doctor to prescribe FDA-approved medications, while they undertake personalized health coaching through our app.

Menten AI designs protein drugs and enzymes using quantum computing and machine learning. Their technology leapfrogs current computational methods making it possible to design previously intractable proteins. The team created the first protein design algorithm for current and near-term quantum computers and created the world’s first protein designed on a quantum computer. They are now working on 3 new proteins, including a peptide to prevent the spread of viruses like Covid-19. They have 2 paid pilot projects with multinational chemical companies and 4 LOI’s with pharma and biotech companies.

Founded in 2010, Lygos is providing biotechnology solutions for today’s renewable chemical challenges. They engineer microbes to convert sugars into high-value, industrial chemicals, targeting compounds where biological production is cost-advantaged over petrochemical production.

YourChoice Therapeutics is revolutionizing the global contraceptive market. Our vision is to develop non-hormonal contraceptives to provide both women and men with birth control options that lack the associated risks of hormone-based options but are equally effective. Traditionally, it has been the women’s financial and health burden to have a contraceptive in place. Our first goal is therefore to bring a novel non-hormonal, on-demand and low cost female contraceptive to the market that will substantially improve their quality of life and well-being. Our second goal is to develop the first ever non-surgical and highly effective non-hormonal contraceptive for men. Currently, male contraception is limited to two main options – vasectomy or condoms. Having such options available to both women and men will globally allow for much better family planning, reduce the number of unwanted pregnancies including abortions and therefore reduce costs and ensure contraceptive health and well-being.

Cancer is a genetic disease. We know this from decades of human and veterinary cancer research. Precision medicine and targeted therapies are successfully used to treat humans with cancer. At FidoCure®, we bring this approach to the world of veterinary medicine. FidoCure® empowers veterinarians to offer genetic sequencing and targeted therapies to treat dogs with cancer. We are committed to expanding the veterinary oncology toolbox for both diagnostics and therapeutics. Our veterinary partners have treated thousands of dogs over the past 30 years and work closely with the growing FidoCure® network of over 143 clinics and 180 forward-thinking veterinary oncologists throughout the US. Together, we can combat canine cancer!

Our mission -To ensure current and future generations have access to clean soil, water & air. -To protect and restore earth's beautiful and diverse ecosystems. -To undo the harm of industrial activity on the planet and ensure future industrial activities are more sustainable. Our research -We develop new bio-based solutions that break down and remove toxic chemicals from the environment.  We also develop bioreactor based solutions which remove toxins from industrial production pipelines, ensuring contaminants are never released into the environment. -To do this, we've partnered with Nature. Specifically, we have harnessed the power of one of Nature's smallest but most powerful technologies: enzymes. Enzymes are everywhere. They break down the food in your stomach, remove dirt from your clothes, and make our beer. At BluumBio, we look for enzymes found in bacteria, algae, plants and other living organisms that naturally degrade toxic chemicals. We then make these enzymes work better in the lab and come up with develop new applications for these technologies.

Medmonk is a technology platform that helps fight non-adherence. It enables pharmacists to provide financial assistance to patients who are unable to pay for their medications. We partner with pharmaceutical companies, pharmacies, physicians, and health plans to improve outcomes by promoting access to chronic therapy. Medmonk is based on the premise that it's in everyone's best interest for medications to be used regardless of price. Patients get the care they need, insurers are protected against larger claims, and pharmaceutical companies and pharmacies get maximum use of their medications.

Bodyport’s cardiovascular sensing weight scale and predictive algorithms detect early changes in cardiac function to help prevent avoidable hospitalizations. Bodyport is initially targeting heart failure, a chronic condition affecting over 6M Americans and a leading cause of hospitalizations (1M/year) and healthcare spending ($35B/year). Bodyport’s novel scale measures cardiac output, congestion, heart rate, and other leading indicators of cardiovascular health — all in the same step patients already take to weigh themselves. Companion algorithms and software empower care teams to quickly identify at-risk patients and remotely optimize their therapy to prevent deterioration.

Curebase is reinventing decentralized clinical trials to help the vast majority of potential patients that currently cannot access clinical research. Curebase’s vision is that any patient, no matter where they are located, should be able to participate in clinical trials at home and with their own doctors. This is made possible through a unique suite of tools, including all-in-one eClinical software and virtual research sites, designed to engage patients in clinical trials across all settings, be it at home, at their local clinic, or other places in their community.

Osmind is the premier platform for clinicians and researchers advancing new life-saving mental health treatments. Today, mental health disorders are one of the leading causes of death worldwide, especially among young adults, and are tied to shortening lifespans. While there have been developments in new psychiatric medications since the first FDA approval in 1954, today there is a growing movement among clinicians, patients, and researchers who are recognizing the need to accelerate new science. The Osmind treatment platform is the first and only solution that solves specific challenges faced by neuropsychiatric clinics, spanning general psychiatry and interventional psychiatry (transcranial magnetic stimulation, ketamine, SPRAVATO®, psychedelic medicine, electroconvulsive therapy). The core electronic health record (EHR) technology is precisely developed for interventional treatment workflows and designed to support a strong therapeutic alliance, including journaling tools and assistance with health plan reimbursement, which is a significant access hurdle for millions of patients. Research from our platform is already helping to set new standards for mental health interventions. For example, in the largest published real-world analysis of ketamine infusion therapy for depression, we teamed up with Stanford University School of Medicine to share findings in the Journal of Affective Disorders (March 2022). We have multiple ongoing research studies leveraging our proprietary real-world data, including an even larger ketamine analysis leveraging machine learning to predict treatment outcomes. Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists. We are backed by top investors including DFJ Growth, General Catalyst, Future Ventures, Tiger Global, and Y Combinator.

Culture Biosciences grows cells for biotech companies. Our customers genetically modify organisms to produce new therapeutics, materials, fuels and foods. We help them quickly run experiments and develop manufacturing processes so they can get their products to market faster. We've built proprietary software and automation systems to make operating our bioreactors more efficient than existing systems. We also provide customers with new software tools that help them analyze and contextualize their data. We are currently serving a number of biotech customers and scaling out our infrastructure.

Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods. Currently, DNA is manufactured via a chemical method that has remained mostly unchanged for 35 years. Our enzyme-based approach promises to dramatically accelerate innovation in biological research and biotechnology, including therapeutics, diagnostics and biomanufacturing.

Archform is teeth aligner software startup that lets orthodontists create, design and 3D print aligners within their own offices. The idea is to provide orthodontists with a way to better compete against some direct-to-consumer teeth aligner startups and cut down on the cost of Invisalign.

Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise. Modulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue. Modulari-T looks to expand its technology to reach every area of cell therapy and become the platform of reference for cell engineering.

Carrot is a simple and affordable way for companies of any size to build or enhance their fertility benefit. Carrot can help with egg freezing, infertility treatments including in vitro fertilization (IVF), LGBT+ conception, and more. Fertility care is daunting and scary; our focus is on improving the employee experience during high impact moments related to fertility-- helping save time, money and stress.

Atomwise is a preclinical tech-enabled biotech using machine learning for hit discovery, hit expansion, and lead optimization. We were the first team to apply convolutional neural networks to drug discovery. We focus on identifying and optimizing novel small molecule scaffolds and unlocking previously-undrugged protein targets.

MentalHappy is a tele-health platform that allows health professionals to facilitate online support groups.The MentalHappy app allows health professionals to facilitate online support groups to help meet the rising demand for mental health services, create meaningful impact and earn extra revenue. Some groups are more intimate, while others have 100+ members, spanning different life events from grief support, healing from illness, life after divorce, black mental health, LGBTQIA+, stress management, emotional fertility support, coping with anxiety, and many other groups.

Perlara 1.0 (Feb 2014 - Feb 2019) launched early R&D joint ventures called PerlQuests with highly motivated rare disease families, companies or impact investors. We screened gene-edited patient avatars for repurposable drugs in order to build a predictive R&D engine called ArkBase. We planned to monetize programs based on ArkBase predictions by selectively spinning out asset-centric clinical development NewCos. Perlara 1.5 (March 2019 - April 2020) was the transition to a one-person virtual clinical development company and when the epalrestat and aripiprazole repurposing trials were launched at Mayo Clinic for the treatment of PMM2-CDG and NGLY1-CDDG, respectively. Perlara 2.0 (May 2020 --> The first decentralized and distributed biotech

At iMicrobes, we believe there are opportunities for biology to solve our biggest problems. Our mission is to work with the world’s largest companies to use new raw materials and recycle waste for chemical production, polymers, agriculture, and space exploration.

Have you ever wondered why it's so hard for physicians to communicate quickly and why the leading cause of preventable death is still a delay in communication? Our team has built the solution for this. Medigram is a team of tier 1 health system CxO IT executives, technologists, SaaS exec, physicians, engineers, and data experts. We have developed a breakthrough service for the medical industry to save lives and for hospitals to make millions per year. Medigram instantly flags insights from clinician chats for immediate insight into hospital operations and patient care. This reduces critical response times by 50%. We've designed this system to provide instant, reliable messaging (including images and audio files) across very complicated network environments in hospitals. Medigram is secure, designed for HIPAA, and a full stack system which includes database back end, middleware, logic, and client apps for iOS, Android, desktop, and the web. Our solution to this is Mobile Intelligence For Healthcare by providing a secure, intelligent workflow management platform for the patient care ecosystem and medical professionals. Within the healthcare environment, you have physicians, the patient care team, EMR, workflow, data, and administration which needs to be tied together with intelligence through Medigram.

Healthcare is delivered by teams – nurses, doctors, and staff, specific to each hospital, clinic, and department. They want to do their best, but cannot keep up with constantly changing information. Burnout >50%. Unprecedented turnover. Growing medical errors (the #3 cause of death in the US). $100B+ in waste. Elemeno Health is a UCSF and Y Combinator-backed B2B SaaS for healthcare facilities– “a playbook in your pocket,” customized to support frontline teams with bite-sized training and communication at their fingertips, accessible 24/7 on any device. Our efficacy is demonstrated in our published results, passionate clients, and consistent renewals. 20x ROI. 75% decrease in medical errors.

At AgileMD, we are building the most advanced real-time predictive analytics and clinical algorithms platform for hospitals. Our cloud-based engine helps thousands of doctors and nurses around the country make medical decisions, so that every patient receives the highest quality and value of care based on the latest medical knowledge and data.

We are a service for people to learn about their personal environmental exposures. Our first product is a urine test for exposure to chemicals in everyday products.

Verge uses artificial intelligence and human data to develop better drugs faster. Verge has an end-to-end technology-driven drug discovery and development platform, featuring one of the field’s largest and most comprehensive proprietary patient genomics datasets from human tissue. Verge uses machine learning to mine this data and develops these insights into new drugs using it’s human-centric biology and chemistry platforms.

Qventus’ mission is to simplify how healthcare operates so it just works — for everyone. The company offers an AI-based software platform that helps hospital teams make better operational decisions in real-time. Qventus addresses operational challenges across the hospital including emergency departments, perioperative areas, patient safety, in-patient, outpatient and pharmacy. Located in Silicon Valley, Qventus is honored to be working with leading public, academic and community hospitals across the United States. Founded in 2012, Qventus was named among Fast Company’s Most Innovative Companies for 2018. The company has also been recognized as a leader and innovator in operational excellence, with the 2016 Fierce Innovations Award in Healthcare and Healthcare Informatics 2017 Innovator Award. For more information about Qventus, please visit www.qventus.com

Synaptiq's mission is to become the AI infrastructure for the $110B medical education industry, leading to better physicians, a more efficient healthcare system, and improved patient care.

SimplyInsured was founded with one mission: to eliminate fear from health insurance. By changing the way small business owners purchase health insurance with our 100% online platform, we’re transforming a $20 billion dollar industry and delighting thousands of customers. Our unique values-based culture (and extremely talented team) is our core competitive advantage, and each person on our team makes a direct, immediate impact on our business. We value transparency, feedback, bias to action, growth, and an obligation to dissent. Every opinion is respected, we hold each other to extremely high standards, we’re driven by the diversity in our backgrounds, and unified by 100% alignment on our mission. What’s best for the customer is the heart of everything we do, and our customer stories prove it: by changing health insurance we’re literally saving lives. Based in San Francisco, SimplyInsured was founded in 2012 and is back by Bessemer Venture Partners, Polaris Ventures, and Y-Combinator. If you’re up for the challenge of improving health insurance for millions of Americans, we’re just getting started, and we’re growing!

Catena’s technology lets us attach any two proteins together using an enzyme and the native amino acids tyrosine and cysteine within target proteins. It is a true platform technology because it enables the joining of any two soluble proteins together with minimal engineering and without restrictions due to protein size or complexity. Our work has already been used to modify cancer specific antibodies, CRISPR proteins and even cell surfaces. Our ability to produce modular protein therapeutics in a fraction of the time allows for true library creation across the therapeutics spectrum from oncology, vaccines, inflammatory disease and beyond.

Abalone Bio developed a technology to find antibody drugs that activate and modulate cell surface receptors, the “antennae” on cells that help convert chemical signals into cellular responses, like growth. Antibodies are a growing class of drugs that have tremendous safety and efficacy advantages over small molecules; 7 of the top 10 selling drugs are antibodies, earning an average of $7B in revenue. However, antibodies- especially ones that activate and modulate cell surface receptors- are hard to find. Abalone Bio expands the playing field for antibody therapeutics and enables us to previously access treatments for untreated diseases. We have already discovered a novel antibody that activates a non-opioid receptor that produces analgesia. We are developing this antibody into a treatment for neuropathic pain – a medical condition that currently is treated with drugs like addictive opiates. The same molecule is also a potential treatment for inflammatory and fibrotic diseases, all 1B+ markets.

Healthcare needs good data. At PicnicHealth, we are building deep real-world datasets fueling cutting-edge research while giving patients control of their own medical record data. These complete, clinically-rich datasets produce unique insights — across dozens of diseases — to ultimately get the right treatments into patients’ hands faster. We work directly with patients and leverage state of the art machine learning to transform messy medical records into structured, research-ready datasets. To date we’ve helped tens of thousands of patients securely access their records and proactively contribute to advancing research in diseases that impacts their lives.

Full Sleep by Koko Labs is the first at-home sleep program that combines the power of clinical grade, radar based wireless sleep tracking with best-in-class CBT-I sleep techniques. Full Sleep delivers daily lessons developed with evidence-based principles. The multi-week curriculum is customized based on your daily overnight sleep data and other health conditions that could impact sleep, such as menopause, chronic pain, or depression. Learn how to challenge assumptions, change habits, and introduce behaviors to help you fall and stay asleep.

We quantify brain health and align patients with the right treatment

We are making coffee for caffeine sensitive people. We do this by producing the world's first caffeine replacement, paraxanthine. It's better than caffeine at waking you up and causes fewer side effects, like anxiety and jitteriness.

Joon is an integrated pediatric digital health platform for kids, starting with behavior disorders like ADHD, autism, anxiety, and depression. In Joon, kids access a game-based digital therapeutic where they level up when they do real-life behaviors that are managed by parents and clinicians. Over the next 10 years, we plan on being the first-line vertically integrated digital treatment for pediatric behavior disorders, leveraging the first of its kind technology to drive behavior change.

REPROSENT is a patient-driven care system that harnesses patients' time to relieve overburdened medical teams. With an app that elevates the role of both patients and their loved ones, REPROSENT helps patients stay on track, capture previously untapped data about their lived experience, and receive timely triage that improves their health outcomes. By making crucial patient information actionable, REPROSENT enables doctors to focus their time on personalized treatment, transforming the way medical care is provided.

Vision Disease cause innumerable cases of preventable blindness globally - 415 million diabetic patients worldwide are susceptible to Diabetic Retinopathy (DR), Glaucoma, and more. Current screening protocols for vision disease require ophthalmologists to manually diagnose patients through visual assessment of the fundus. Given the large number of diabetes patients in various communities, this process is expensive, inefficient, and an undue burden on eye clinics.

Pandan uses AI to help health insurers identify and fix operational issues. For example, insurers lose Medicaid revenue when a patient condition like diabetes is missing from a claim. Pandan makes it simple to detect and fix this issue quickly.

Shasqi is leading the development of therapeutics leveraging click chemistry to get active cancer treatments to tumors with its proprietary CAPAC™ platform. Our technology is based on localizing a click chemistry reagent in the tumor area, which then activates a second agent, a systemically infused protodrug. When the two 'click', a powerful localized therapy is activated at the tumor, while keeping its systemic exposure levels below toxic thresholds.

The Human Diagnosis Project (also referred to as “Human Dx” or “the Project”) is a worldwide effort to build an open medical intelligence system that maps the steps to help any patient. By combining collective intelligence with machine learning, Human Dx intends to enable more accurate, affordable, and accessible care for all

Forty million men in the US and over 500 million worldwide suffer from urinary obstruction related to benign prostatic hyperplasia (BPH). The majority of men will experience symptoms of this disease at some point in life. BPH, also known as prostate enlargement, leads to urinary straining, frequency, urgency, and sleep disruption. Despite the high prevalence and significant quality of life burden of BPH, established treatments are limited to drugs, which have limited effectiveness, and surgery, which carries a high risk of sexual side effects. The Zenflow Spring is a small implant delivered in the urologist's office in a simple procedure that provides quick and long-lasting symptom relief.

Modern Health is the leading mental wellness platform that combines clinically validated assessments, personalized stress management support, an international network of certified behavioral health coaches, and licensed therapists to deliver mental health support across a broad range of individual needs. Modern Health empowers employers to lead the charge in helping their employees be less stressed, more engaged, and happier through evidence-based technology and professional support. Modern Health has raised over $170M from top investors Battery Ventures, Kleiner Perkins, Founders Fund, and John Doerr and supports over 200 companies globally including Lyft, Pixar, SoFi, Credit Karma, Electronic Arts, Cooley, and Okta.

Zeit Medical leverages the power of AI and wearable sensors to deliver peace of mind for those affected by stroke. Zeit’s smart headband immediately detects the onset of stroke and notifies 911. Each year more than 90% of the one million strokes in the US go untreated, resulting in life-long disability and exploding medical costs north of $100b. The lack of timely treatment is the result of delays in alerting the emergency services. More than 10 million Americans with an elevated stroke risk live with constant fear that a stroke may go unnoticed for hours, while they are asleep or alone. The company was founded by Orestis Vardoulis PhD a biomedical & mechanical engineer and expert in digital health (EPFL/Stanford) and Urs Naber MD a critical care physician (Dartmouth/Stanford). They have both seen the devastating effects of stroke in their families and came up with the idea of addressing this unmet clinical need during their Stanford Biodesign Innovation Fellowship.

We provide free digital mental health technologies for millions of people struggling online — particularly young people. For example, we partner with online communities to help find and treat at-risk individuals directly on their platform using our online interventions.

At Athelas, we're bringing simple, life-changing health care products to people around the globe. The future of healthcare is at the home - we are a team of technologists building the next generation of medical products at the intersection of hardware and software. We won’t stop until we’ve brought the world class tools of a hospital to your home. Athelas Remote Patient Monitoring (RPM) allows healthcare providers to monitor patient vitals like blood pressure, weight, and blood glucose without the patient ever having to enter a clinic, improving patient health and engagement, and reducing hospitalizations. We do this all through a beautifully integrated suite of devices and software tools that provides access to state-of-the-art technologies and groundbreaking AI powered analysis.

The world’s No. 1 lab management platform. We help scientists easily organize orders, manage inventory, and save money.

Slingshot is AI that analyzes medical records to determine if the diagnosis is supported by the clinical evidence. The company is founded by Pranov Duggasani, a former Google and Microsoft AI engineer, and Zoe Holderness, a former Lyft and Tesla engineer. They started working on Slingshot after facing their own frustrations with inflated and erroneous medical bills with the goal to save patients more money with less work.

Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes. Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhoea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.

Delivery of TERT mRNA extends telomeres sufficiently in a few days to reverse over a decade of telomere shortening during normal aging. We are advancing TERT mRNA-based therapies to the clinic.

We are developing a drug to increase metabolism and burn calories without exercise. Obesity and type 2 diabetes have reached epidemic proportions. There are 2.2B overweight people and 500M people with type 2 diabetes worldwide, and these numbers increase drastically every year. Existing drugs are not effective enough to reverse the trend. Our drug can solve this problem, because it addresses the root cause of metabolic disorders – the imbalance between caloric intake and expenditure. Our drug will target mitochondria – the powerhouse of the cell – to generate heat. This approach has been proven to fully reverse obesity and type 2 diabetes in animals. However, therapeutic application for humans was impossible, because mitochondrial heat production could only be induced by highly artificial methods with side effects. This changed after our recent breakthrough discovery of the protein that mitochondria naturally use to generate heat. We have developed a unique high-throughput drug discovery platform to identify compounds that selectively activate this target protein, without side effects. For decades people have wanted a drug that burns calories like exercise does. We are realizing this dream at Equator Therapeutics.

Our lead candidate is a multifaceted attack antibody for ovarian cancer. Our approach enables targeting primary cancer cells directly, alongside enabling the immune system's natural anti-cancer function, all with one therapeutic antibody.

Novel quantitative virtual microscopy for early detection of Alzheimer's disease from non-invasive MRI.

Over 80% of maternal mortalities were preventable with earlier intervention. Currently, doctors miss >50% of moms who have life-threatening complications and wait until labor to start doing manual risk assessments, at which point it's too late. Elythea's proprietary ML models catch life-threatening obstetric complications (like postpartum hemorrhage, preeclampsia/eclampsia, emergency c-section, preterm labor, and more) as soon as the first visit. We automatically analyze relevant demographic and clinical risk factors, flag high-risk patients, and provide evidence-based interventions, giving doctors months in advance to intervene and prevent complications from ever happening. Our global clinical studies have shown that we can catch 2-3x more complications than clinical judgment 10x sooner.

Blueberry Medical provides concierge pediatric care with at-home medical diagnostics and an always-available team of Pediatricians. Blueberry handles twice as may illnesses as any other telemedicine provider and has proven to reduce ER costs by 50%.

Medplum makes it easy to build healthcare webapps that are compliant and interoperability ready. Our open source toolkit allows healthcare providers write apps that are HIPAA compliant, SOC2 certified and FHIR native - streamlining payor connections, health system integrations and more.

Our API-connected healthcare infrastructure empowers our partners to deliver world-class patient experiences. We power prescribing, lab testing and pharmacy fulfillment.

We help healthcare companies run their practices. Eligibility, BI, claims, patient payments? Shoot us an email at founders@aperohealth.com Apero is a Y-Combinator-backed startup based in San Francisco bringing transparency and ease to medical billing. As one of the top startups from the Summer 2019 Y Combinator batch, we have raised from well-known investors including the creator of Gmail Paul Buchheit and the founders of Doctor on Demand, Gusto and Reddit, and serve startups that have raised over $1B in Venture Capital. The founding team are Stanford CS and Berkeley grads and include the CTO of Doctor on Demand having helped raised $240m and process millions of video calls. We are also hiring for engineers and product-minded operations people interested in giving price transparency to patients and providers. We serve practices nationwide, and integrate with leading EHRs as well.

Bunkerhill is a Sequoia-backed company whose goal is to increase the adoption of AI in healthcare, in order to help doctors catch deadly diseases earlier. Bunkerhill Health has built a consortium of research institutions (Stanford, Johns Hopkins, Harvard, etc.), who develop and validate AI algorithms seamlessly under our legal umbrella (less than one week of setup time for a new project when using the Bunkerhill consortium, versus a year or more for projects outside the consortium). Bunkerhill then manages the FDA clearance and commercial sales process for the algorithms that these institutions develop and validate with us. We’ve signed commercial contracts and deployed algorithms with the world’s leading health systems—UCSF, Mayo Clinic, Georgetown/MedStar, and several others. These algorithms help doctors identify patients earlier than has otherwise been possible, leading to better treatment outcomes (early clinical screening for heart disease, pancreatic cancer, etc.) We’re backed by world class investors: Sequoia, Max Levchin (co-founder of PayPal and Affirm), YC, DCVC, and Pacific8.

Rinse is building the One Medical for dental. Beautiful studios, easy to book same day appointments, and anxiety-free care focused on prevention, not the upsell.

Our mission is simple: challenge archaic rules and implied medical conventions in healthcare to better serve patients and physicians. Gradia is the backbone of the entire patient experience, helping patients get personalized, high-touch care while also making clinics more money. With our software patients can stay informed/educated about the status of their care, easily communicate with their providers, and get direct access to a specialized virtual care team. Our software is currently at several clinics across the Southeastern US and helping thousands of patients get the care they deserve. 

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. Asher Bio is backed by Third Rock Ventures and is located in South San Francisco.

Alzheimer’s is tough. And while there is no cure, getting help should be 100x easier than it is today. We’ve raised over $6 million to solve that problem. When someone is going through the disease, there are many different things they need help with (i.e. memory issues, depression, fall risk, safety in the home, etc). The primary person responsible for that care is one of the patient’s loved ones – usually a child or a spouse. That’s a really difficult thing for the loved one to do. It’s stressful, time consuming, and difficult. If we can make their lives easier, we can not only improve their experience but also create better patient outcomes. We’re building the world’s first one-stop-shop, d2c care platform for Alzheimer’s, starting by optimizing the care monitoring, management, and intervention processes.

Endpoint Health is on a mission to address urgent needs in immune-driven critical and chronic illnesses by delivering therapies that are personalized to each patient’s biology. We built Endpoint Health from the ground up to develop and commercialize therapeutics and therapy-guiding tests, to ensure that every patient receives personalized treatment that will dramatically improve their outcomes. Our vision is a world in which all patients have effective, personalized treatment, because therapies are targeted to the right patient at the right time.

We go to nursing homes, and we put an internet-connected bed sensor underneath all their beds. Our app gives nurses valuable insights and an overview of all their residents. We reduce fall incidents and bedsores while improving evening and night shift productivity by over 30%. Momo Medical solves the biggest problem affecting nursing homes, staff shortages while increasing the quality of care.

Nourish is solving America's healthcare crisis by helping people eat better. We connect chronic condition patients with a Registered Dietitian via telehealth and get it covered by their health insurance.

SmartSpot is a post Series-A stealth startup backed by Founders Fund and Khosla Ventures that uses computer vision to deliver an unparalleled fitness training experience to your home. Our unique hardware solution gives amazing trainers the ability to see their class participants in real time and deliver detailed advice that was previously only possible in person.

Today 90% of people can't afford to visit a Dermatologist. Our apps automatically analyze the skin or hair using our AI technology and then deliver a customized treatment kit to the customers' doorstep. We have 2 brands: 1. MDacne - the #1 dermatology app in the US & UK App Store. Millions have downloaded MDacne to analyze their acne and get a customized treatment kit. 2. MDhair - the first-ever fully customized hair regrowth treatment kit. Using MDhair, people with hair loss can analyze a picture of their scalp and get a personalized hair regrowth treatment. Our team combines the highest levels of expertise in dermatology, AI, and digital marketing. Come and join us on the mission to build the future of Dermatology!

We're a primary care practice that helps residents of senior living communities lead healthier, happy lives. Our mission is to keep senior living residents healthy—by keeping them away from hospitals where exposure to health risks is high. Through our new clinical care delivery model, we bring clinicians right into senior living communities, providing safer, more convenient primary care. Pine Park partners with senior living communities to provide primary care to their residents, building a value-based care model where we keep patients healthier. This allows us to provide comprehensive healthcare on-site, see patients regularly, and better support their holistic health.

Building a standard-of-care medical device to freeze abnormal cells before they become cervical cancer, in any clinic, anywhere in the world, at 1/10 the cost. -- Ananya Health is building a portable cryoablation unit designed for every primary care clinic in the world. Our beachhead application is cervical cancer prevention -- even though cervical cancer is easy to screen for, 80% of clinics worldwide lack the infrastructure and specialized staff to treat at the earliest stages. Our platform technology allows nurses and lower level health workers to treat at the point of care for 1/10 the cost of traditional ablation, and is the only cryo device that will help us achieve the WHO target to eliminate cervical cancer in our lifetime.